| 產(chǎn)品編號 | bsm-33203M-AP |
| 英文名稱 | Mouse Anti-HSP27/AP Conjugated antibody |
| 中文名稱 | 堿性磷酸酶（AP）標記的熱休克蛋白27單克隆抗體 |
| 別 名 | Heat shock 27kDa protein; 28 kDa heat shock protein; CMT2F; DKFZp586P1322; Estrogen regulated 24 kDa protein; Estrogen-regulated 24 kDa protein; Heat shock 25kDa protein 1; Heat shock 25kDa protein 1; Heat shock 27 kDa protein; Heat shock 27kD protein 1; Heat shock 27kDa protein 1; Heat shock 27kDa protein 1; Heat shock 28kDa protein 1; Heat shock 28kDa protein 1; Heat Shock Protein 27; Heat Shock Protein 27; Heat shock protein beta 1; Heat shock protein beta-1; Heat Shock Protein27; Heat Shock Protein27; HMN2B; HS.76067; Hsp 25; Hsp 25; Hsp 27; Hsp 27; Hsp 28; Hsp 28; Hsp B1; Hsp B1; Hsp25; Hsp25; HSP27; Hsp28; Hsp28; HspB1; HspB1; HSPB1_HUMAN; SRP27; Stress responsive protein 27; Stress-responsive protein 27. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 免疫學 信號轉(zhuǎn)導 |
| 抗體來源 | Mouse |
| 克隆類型 | Monoclonal |
| 克 隆 號 | 1G12 |
| 交叉反應(yīng) | Human, |
| 產(chǎn)品應(yīng)用 | WB=1:50-200 IHC-P=1:50-200 IHC-F=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 27kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | Recombinant human HSP27 Protein |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein G |
| 儲 存 液 | Constituents: 0.05M TBS, pH 8.0 with 10mg/ml BSA and 0.05% NaN3, 50% glycerol. Or Lyophilized. Buffer = 0.05M TBS, pH 8.0 with 10mg/ml BSA and 0.05% NaN3. Reconstitute with sterile distilled water. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The protein encoded by this gene is induced by environmental stress and developmental changes. The encoded protein is involved in stress resistance and actin organization and translocates from the cytoplasm to the nucleus upon stress induction. Defects in this gene are a cause of Charcot-Marie-Tooth disease type 2F (CMT2F) and distal hereditary motor neuropathy (dHMN). [provided by RefSeq, Oct 2008] Function: Involved in stress resistance and actin organization. Subunit: Interacts with TGFB1I1. Associates with alpha- and beta-tubulin, microtubules and CRYAB. Interacts with HSPB8 and HSPBAP1. Subcellular Location: Cytoplasm. Nucleus. Cytoplasm, cytoskeleton, spindle. Note=Cytoplasmic in interphase cells. Colocalizes with mitotic spindles in mitotic cells. Translocates to the nucleus during heat shock and resides in sub-nuclear structures known as SC35 speckles or nuclear splicing speckles. Tissue Specificity: Detected in all tissues tested: skeletal muscle, heart, aorta, large intestine, small intestine, stomach, esophagus, bladder, adrenal gland, thyroid, pancreas, testis, adipose tissue, kidney, liver, spleen, cerebral cortex, blood serum and cerebrospinal fluid. Highest levels are found in the heart and in tissues composed of striated and smooth muscle. Post-translational modifications: Phosphorylated in MCF-7 cells on exposure to protein kinase C activators and heat shock. Phosphorylation by MAPKAPK2 and MAPKAPK3 in response to stress leads to dissociate HSP27/HSPB1 from large small heat-shock protein (sHsps) oligomers and impair its chaperone activity and ability to protect against oxidative stress effectively. Phosphorylation by MAPKAPK5 in response to PKA stimulation induces F-actin rearrangement. DISEASE: Defects in HSPB1 are the cause of Charcot-Marie-Tooth disease type 2F (CMT2F) [MIM:606595]. CMT2F is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. Nerve conduction velocities are normal or slightly reduced. CMT2F onset is between 15 and 25 years with muscle weakness and atrophy usually beginning in feet and legs (peroneal distribution). Upper limb involvement occurs later. CMT2F inheritance is autosomal dominant. Defects in HSPB1 are a cause of distal hereditary motor neuronopathy type 2B (HMN2B) [MIM:608634]. Distal hereditary motor neuronopathies constitute a heterogeneous group of neuromuscular disorders caused by selective impairment of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. Similarity: Belongs to the small heat shock protein (HSP20) family. Database links: Entrez Gene: 3315 Human Entrez Gene: 15507 Mouse Omim: 602195 Human SwissProt: P04792 Human SwissProt: P14602 Mouse Unigene: 3849 Dog Unigene: 520973 Human Unigene: 13849 Mouse Unigene: 3841 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 信號傳導（Signaling Intermediates） 適用組織：石蠟切片 細胞定位：胞漿和部分胞核 HSPs是細胞受應(yīng)激原刺激后誘導產(chǎn)生的一組應(yīng)激蛋白，與腫瘤發(fā)生、 增殖及分化有關(guān)。按其分子量不同可分為3種類型，每組的HSPs的分布及功能有所不同。 熱休克蛋白27是人體中最常見而又最小的熱休克蛋白。HSP27和其它HSPs可能與腫瘤耐藥和腫瘤的分化程度以及病人的預后有關(guān)。 |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
